List of Yondelis drug patents

Yondelis is owned by Janssen Prods.

Yondelis contains Trabectedin.

Yondelis has a total of 2 drug patents out of which 0 drug patents have expired.

Yondelis was authorised for market use on 23 October, 2015.

Yondelis is available in powder;intravenous dosage forms.

The generics of Yondelis are possible to be released after 07 July, 2028.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8895557 JANSSEN PRODS Pharmaceutical formulations of ecteinascidin compounds
Jan, 2028

(4 years from now)

US8895557

(Pediatric)

JANSSEN PRODS Pharmaceutical formulations of ecteinascidin compounds
Jul, 2028

(5 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Oct 23, 2022
Pediatric Exclusivity (PED) Apr 23, 2023

Drugs and Companies using TRABECTEDIN ingredient

Market Authorisation Date: 23 October, 2015

Treatment: NA

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of YONDELIS before it's patent expiration?
More Information on Dosage

YONDELIS family patents

3

United States

2

Argentina

2

Peru

2

China

1

Austria

1

Hong Kong

1

RS

1

Korea, Republic of

1

Brazil

1

Australia

1

Poland

1

Malaysia

1

Ukraine

1

Guatemala

1

Uruguay

1

Jordan

1

Spain

1

Germany

1

Israel

1

Cyprus

1

Mexico

1

Japan

1

Slovenia

1

United Kingdom

1

South Africa

1

Portugal

1

El Salvador

1

Russia

1

Croatia

1

Panama

1

Norway

1

New Zealand

1

Honduras

1

Canada

1

Taiwan, Province of China

1

Denmark

1

European Union

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in